We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -146.00 | -1.32% | 10,878.00 | 10,884.00 | 10,886.00 | 10,966.00 | 10,822.00 | 10,882.00 | 1,307,341 | 16:35:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.34 | 168.75B |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) reported negative results from a phase 3 trial of its cancer drug Imfinzi on Friday.
The company said the Mystic trial, which examined Imfinzi as a treatment for previously untreated patients with metastatic nonsmall-cell lung cancer, didn't meet its primary objective. Patients being treated with either Imfinzi alone, or the drug plus tremelimumab, didn't demonstrate a statistically significant improvement in overall survival when compared with platinum-based chemotherapy, it said.
Imfinzi is approved as a treatment for inoperable stage 3 nonsmall-cell lung cancer in more than 40 countries. It's currently being tested in a number of phase 3 trials as a treatment for stage 4 nonsmall-cell lung cancer, the Anglo-Swedish pharmaceutical company said.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 16, 2018 02:30 ET (07:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
